Earnings call Nektar ended 2025 with $245.8M in cash and no debt, bolstered by an additional $476M in early 2026. REZPEG advanced to phase 3 in atopic dermatitis with phase 3 initiation set for June ...

The microbiome manufacturing market shows significant growth potential due to increasing interest in microbiome-targeted therapies for various conditions. Key opportunities exist for contract ...

In the realm of cellular biology, programmed cell death (PCD) stands as a pivotal process governing the elimination of cells, thereby maintaining tissue homeostasis and ensuring an organism's health ...